Mannkind's inhaled insulin meets non-inferiority endpoint in Phase III
This article was originally published in Scrip
Executive Summary
Mannkind's Afrezza, an inhaled insulin, was non-inferior to Lilly's Humalog, an injectable fast-acting insulin analogue, when used as an adjunct to Sanofi-Aventis's Lantus (insulin glargine) therapy, show top-line data from a Phase III trial. Mannkind's share price closed up 12% on the news, to $6.25 on Nasdaq, on 10 June 2010.